Product Code: PM1297
The global intravenous immunoglobulin market size is expected to reach USD 24.13 billion by 2032, according to a new study by Polaris market research. The report "Intravenous immunoglobulin Market Share, Size, Trends, Industry Analysis Report, By Route of Administration (Intravenous, Subcutaneous); By Component; By Application; By End-user; By Distribution Channel; By Region; Segment Forecast, 2023- 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Advancements in plasma fractionation techniques and manufacturing processes have made Intravenous Immunoglobulin (IVIG) products safer and more effective. Thanks to recombinant technologies and purification methods, immunoglobulin products are now highly refined and concentrated, which reduces the chance of adverse reactions and enables more precise therapies. These developments have improved the efficacy of IVIG for primary immune deficiencies, certain autoimmune disorders, and created opportunities for developing novel immunoglobulin-based treatments that can improve patient outcomes. Ongoing research has revealed new therapeutic indications for neurological conditions such as chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, and myasthenia gravis. The expansion of symptoms treated with IVIG provides a wider market potential for immunoglobulin-based therapies, which can benefit more people.
The global market for intravenous immunoglobulin saw a surge due to the COVID-19 pandemic. Research conducted in December 2020, named "COVID-19 in patients with primary and secondary immunodeficiency: The U.K. experience", found that 70% out of 100 people with symptomatic secondary immunodeficiency (SID), primary immunodeficiency (PID), autoinflammatory diseases, and C1 inhibitor deficiency were infected with the SARS-CoV-2 virus and 59% of them were admitted to hospitals, with 8% of them losing their lives. This highlights the fact that immunocompromised individuals are at a higher risk of getting COVID-19, leading to an expected increase in the demand for intravenous immunoglobulin therapy to combat the pandemic.
Virtual trials offer numerous advantages, including remote data collection, increased participant engagement, and larger population inclusion. They minimize risks associated with in-person visits and reduce the burden on participants, coordinators, and investigators. By leveraging virtual methods, the clinical trials industry can overcome challenges, improve efficiency, and facilitate prompt and effective data collection.
Intravenous immunoglobulin Market Report Highlights
During the forecast period, the IgG segment is expected to be the largest. IgG has been extensively researched in clinical trials, which has resulted in its widespread use and acceptance in the medical field. These studies have demonstrated IgG's efficacy and safety in treating various autoimmune disorders, neurological conditions, and other immune-related diseases.
The immunodeficiency diseases segment held the largest market share in 2022. Immunodeficiency diseases can be categorized into two types: primary (inherited) and secondary (acquired). Primary immunodeficiencies are typically genetic and present from birth, while secondary immunodeficiencies can develop later in life due to factors such as infections, medications, or medical treatments.
Hospitals accounted for the highest share in 2022. Hospital pharmacies monitor patients receiving IVIG therapy, collaborate with healthcare professionals to track patient progress, and report any adverse events or reactions to regulatory bodies.
In 2022, the global market was dominated by the North America region. This is because North America has a highly advanced healthcare infrastructure that supports the growth of the IVIG market in the region. With a rising number of cancer patients and the presence of key players such as Baxter International Inc., effective drugs are increasingly being introduced into the market. Furthermore, major pharmaceutical companies in North America invest heavily in research and development, clinical trials, and marketing strategies, which in turn drives the growth of the IVIG market.
The global key market players include: Baxter International Inc., BDI Pharma Inc., Biotest AG, China Biologics Products Inc., CSL Behring, Grifols SA, Kedrion Biopharma, LFB Biotechnologies, Octapharma AG
Polaris market research has segmented the Intravenous immunoglobulin market report based on component, route of administration, application, end-users, distribution channel and region:
Intravenous immunoglobulin, Component Outlook (Revenue - USD Billion, 2019 - 2032)
Intravenous immunoglobulin, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)
Intravenous immunoglobulin, Application Outlook (Revenue - USD Billion, 2019 - 2032)
- Hypogammaglobulinemia
- Chronic Inflammatory demyelinating polyneuropathy (CIDP)
- Immunodeficiency diseases
- Myasthenia Gravis
- Multifocal motor neuropathy
- Idiopathic thrombocytopenic purpura (ITP)
- Inflammatory myopathies
- Specific antibody deficiency
- Guillain-Barre syndrome
Intravenous immunoglobulin, End-Users Outlook (Revenue - USD Billion, 2019 - 2032)
- Hospitals
- Homecare
- Specialty Clinics
Intravenous immunoglobulin, Distribution channels Outlook (Revenue - USD Billion, 2019 - 2032)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
Intravenous immunoglobulin, Regional Outlook (Revenue - USD Billion, 2019 - 2032)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Latin America
- Argentina
- Brazil
- Mexico
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
3. Research Methodology
- 3.1. Overview
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Intravenous Immunoglobulin Market Insights
- 4.1. Intravenous immunoglobulin - Industry Snapshot
- 4.2. Intravenous immunoglobulin Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. The number of people suffering from immunodeficiency disorders is on the rise.to drive the market growth
- 4.2.1.2. Adoption of immunoglobulin-based therapies, drive the market
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High risk of transmission, hinder the market growth
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTLE Analysis
- 4.5. Intravenous immunoglobulin Industry Trends
- 4.6. COVID-19 Impact Analysis
5. Global Intravenous immunoglobulin Market, by Component
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Intravenous Immunoglobulin Market, by Component, 2019-2032 (USD Billion)
- 5.3. IGG
- 5.3.1. Global Intravenous Immunoglobulin Market, by IGG, by Region, 2019-2032 (USD Billion)
- 5.4. IGA
- 5.4.1. Global Intravenous Immunoglobulin Market, by IGA, by Region, 2019-2032 (USD Billion)
- 5.5. IGM
- 5.5.1. Global Intravenous Immunoglobulin Market, by IGM, by Region, 2019-2032 (USD Billion)
- 5.6. IGE
- 5.6.1. Global Intravenous Immunoglobulin Market, by IGE, by Region, 2019-2032 (USD Billion)
- 5.7. IGD
- 5.7.1. Global Intravenous Immunoglobulin Market, by IGD, by Region, 2019-2032 (USD Billion)
6. Global Intravenous immunoglobulin Market, by Route of Administration
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
- 6.3. Intravenous
- 6.3.1. Global Intravenous immunoglobulin Market, by Intravenous, by Region, 2019-2032 (USD Billion)
- 6.4. Subcutaneous
- 6.4.1. Global Intravenous immunoglobulin Market, by Subcutaneous, by Region, 2019-2032 (USD Billion)
7. Global Intravenous immunoglobulin Market, by Application
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
- 7.3. Hypogammaglobulinemia
- 7.3.1. Global Intravenous immunoglobulin Market, by Hypogammaglobulinemia, by Region, 2019-2032 (USD Billion)
- 7.4. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
- 7.4.1. Global Intravenous immunoglobulin Market, by Chronic Inflammatory demyelinating polyneuropathy (CIDP), by Region, 2019-2032 (USD Billion)
- 7.5. Immunodeficiency diseases
- 7.5.1. Global Intravenous immunoglobulin Market, by Immunodeficiency diseases, by Region, 2019-2032 (USD Billion)
- 7.6. Myasthenia Gravis
- 7.6.1. Global Intravenous immunoglobulin Market, by Myasthenia Gravis, by Region, 2019-2032 (USD Billion)
- 7.7. Multifocal motor neuropathy
- 7.7.1. Global Intravenous immunoglobulin Market, by Multifocal motor neuropathy, by Region, 2019-2032 (USD Billion)
- 7.8. Idiopathic thrombocytopenic purpura (ITP)
- 7.8.1. Global Intravenous immunoglobulin Market, by Idiopathic thrombocytopenic purpura (ITP), by Region, 2019-2032 (USD Billion)
- 7.9. Inflammatory myopathies
- 7.9.1. Global Intravenous immunoglobulin Market, by Inflammatory myopathies, by Region, 2019-2032 (USD Billion)
- 7.10. Specific antibody deficiency
- 7.10.1. Global Intravenous immunoglobulin Market, by Specific antibody deficiency, by Region, 2019-2032 (USD Billion)
- 7.11. Guillain-Barre syndrome
- 7.11.1. Global Intravenous immunoglobulin Market, by Guillain-Barre syndrome, by Region, 2019-2032 (USD Billion)
8. Global Intravenous immunoglobulin Market, by End Users
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Global Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
- 8.3. Hospitals
- 8.3.1. Global Intravenous immunoglobulin Market, by Hospitals, by Region, 2019-2032 (USD Billion)
- 8.4. Homecare
- 8.4.1. Global Intravenous immunoglobulin Market, by Homecare, by Region, 2019-2032 (USD Billion)
- 8.5. Specialty Clinics
- 8.5.1. Global Intravenous immunoglobulin Market, by Specialty Clinics, by Region, 2019-2032 (USD Billion)
9. Global Intravenous immunoglobulin Market, by Distribution Channel
- 9.1. Key Findings
- 9.2. Introduction
- 9.2.1. Global Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.3. Hospital Pharmacy
- 9.3.1. Global Intravenous immunoglobulin Market, by Hospital Pharmacy, by Region, 2019-2032 (USD Billion)
- 9.4. Retail Pharmacy
- 9.4.1. Global Intravenous immunoglobulin Market, by Retail Pharmacy, by Region, 2019-2032 (USD Billion)
- 9.5. Online Pharmacies
- 9.5.1. Global Intravenous immunoglobulin Market, by Online Pharmacies, by Region, 2019-2032 (USD Billion)
10. Global Intravenous immunoglobulin Market, by Geography
- 10.1. Key findings
- 10.2. Introduction
- 10.2.1. Intravenous immunoglobulin Market Assessment, By Geography, 2019-2032 (USD Billion)
- 10.3. Intravenous immunoglobulin Market - North America
- 10.3.1. North America: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
- 10.3.2. North America: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
- 10.3.3. North America: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
- 10.3.4. North America: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
- 10.3.5. North America: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
- 10.3.6. Intravenous immunoglobulin Market - U.S.
- 10.3.6.1. U.S.: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
- 10.3.6.2. U.S.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
- 10.3.6.3. U.S.: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
- 10.3.6.4. U.S.: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
- 10.3.6.5. U.S.: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
- 10.3.7. Intravenous immunoglobulin Market - Canada
- 10.3.7.1. Canada: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
- 10.3.7.2. Canada.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
- 10.3.7.3. Canada: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
- 10.3.7.4. Canada: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
- 10.3.7.5. Canada: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
- 10.4. Intravenous immunoglobulin Market - Europe
- 10.4.1. Europe: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
- 10.4.2. Europe.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
- 10.4.3. Europe: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
- 10.4.4. Europe: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
- 10.4.5. Europe: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
- 10.4.6. Intravenous immunoglobulin Market - UK
- 10.4.6.1. UK: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
- 10.4.6.2. UK.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
- 10.4.6.3. UK: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
- 10.4.6.4. UK: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
- 10.4.6.5. UK: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
- 10.4.7. Intravenous immunoglobulin Market - France
- 10.4.7.1. France: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
- 10.4.7.2. France.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
- 10.4.7.3. France: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
- 10.4.7.4. France: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
- 10.4.7.5. France: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
- 10.4.8. Intravenous immunoglobulin Market - Germany
- 10.4.8.1. Germany: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
- 10.4.8.2. Germany.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
- 10.4.8.3. Germany: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
- 10.4.8.4. Germany: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
- 10.4.8.5. Germany: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
- 10.4.9. Intravenous immunoglobulin Market - Italy
- 10.4.9.1. Italy: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
- 10.4.9.2. Italy.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
- 10.4.9.3. Italy: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
- 10.4.9.4. Italy: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
- 10.4.9.5. Italy: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
- 10.4.10. Intravenous immunoglobulin Market - Spain
- 10.4.10.1. Spain: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
- 10.4.10.2. Spain.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
- 10.4.10.3. Spain: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
- 10.4.10.4. Spain: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
- 10.4.10.5. Spain: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
- 10.4.11. Intravenous immunoglobulin Market - Netherlands
- 10.4.11.1. Netherlands: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
- 10.4.11.2. Netherlands.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
- 10.4.11.3. Netherlands: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
- 10.4.11.4. Netherlands: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
- 10.4.11.5. Netherlands: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
- 10.4.12. Intravenous immunoglobulin Market - Russia
- 10.4.12.1. Russia: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
- 10.4.12.2. Russia.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
- 10.4.12.3. Russia: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
- 10.4.12.4. Russia: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
- 10.4.12.5. Russia: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
- 10.5. Intravenous immunoglobulin Market - Asia Pacific
- 10.5.1. Asia Pacific: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
- 10.5.2. Asia Pacific.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
- 10.5.3. Asia Pacific: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
- 10.5.4. Asia Pacific: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
- 10.5.5. Asia Pacific: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
- 10.5.6. Intravenous immunoglobulin Market - China
- 10.5.6.1. China: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
- 10.5.6.2. China.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
- 10.5.6.3. China: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
- 10.5.6.4. China: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
- 10.5.6.5. China: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
- 10.5.7. Intravenous immunoglobulin Market - India
- 10.5.7.1. India: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
- 10.5.7.2. India.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
- 10.5.7.3. India: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
- 10.5.7.4. India: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
- 10.5.7.5. India: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
- 10.5.8. Intravenous immunoglobulin Market - Japan
- 10.5.8.1. Japan: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
- 10.5.8.2. Japan.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
- 10.5.8.3. Japan: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
- 10.5.8.4. Japan: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
- 10.5.8.5. Japan: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
- 10.5.9. Intravenous immunoglobulin Market - Malaysia
- 10.5.9.1. Malaysia: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
- 10.5.9.2. Malaysia.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
- 10.5.9.3. Malaysia: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
- 10.5.9.4. Malaysia: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
- 10.5.9.5. Malaysia: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
- 10.5.10. Intravenous immunoglobulin Market - Indonesia
- 10.5.10.1. Indonesia: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
- 10.5.10.2. Indonesia.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
- 10.5.10.3. Indonesia: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
- 10.5.10.4. Indonesia: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
- 10.5.10.5. Indonesia: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
- 10.5.11. Intravenous immunoglobulin Market - South Korea
- 10.5.11.1. South Korea: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
- 10.5.11.2. South Korea.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
- 10.5.11.3. South Korea: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
- 10.5.11.4. South Korea: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
- 10.5.11.5. South Korea: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
- 10.6. Intravenous immunoglobulin Market - Middle East & Africa
- 10.6.1. Middle East & Africa: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
- 10.6.2. Middle East & Africa: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
- 10.6.3. Middle East & Africa: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
- 10.6.4. Middle East & Africa: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
- 10.6.5. Middle East & Africa: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
- 10.6.6. Intravenous immunoglobulin Market - Saudi Arabia
- 10.6.6.1. Saudi Arabia: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
- 10.6.6.2. Saudi Arabia.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
- 10.6.6.3. Saudi Arabia: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
- 10.6.6.4. Saudi Arabia: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
- 10.6.6.5. Saudi Arabia: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
- 10.6.7. Intravenous immunoglobulin Market - UAE
- 10.6.7.1. UAE: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
- 10.6.7.2. UAE.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
- 10.6.7.3. UAE: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
- 10.6.7.4. UAE: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
- 10.6.7.5. UAE: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
- 10.6.8. Intravenous immunoglobulin Market - Israel
- 10.6.8.1. Israel: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
- 10.6.8.2. Israel.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
- 10.6.8.3. Israel: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
- 10.6.8.4. Israel: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
- 10.6.8.5. Israel: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
- 10.6.9. Intravenous immunoglobulin Market - South Africa
- 10.6.9.1. South Africa: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
- 10.6.9.2. South Africa.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
- 10.6.9.3. South Africa: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
- 10.6.9.4. South Africa: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
- 10.6.9.5. South Africa: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
- 10.7. Intravenous immunoglobulin Market - Latin America
- 10.7.1. Latin America: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
- 10.7.2. Latin America.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
- 10.7.3. Latin America: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
- 10.7.4. Latin America: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
- 10.7.5. Latin America: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
- 10.7.6. Intravenous immunoglobulin Market - Mexico
- 10.7.6.1. Mexico: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
- 10.7.6.2. Mexico.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
- 10.7.6.3. Mexico: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
- 10.7.6.4. Mexico: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
- 10.7.6.5. Mexico: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
- 10.7.7. Intravenous immunoglobulin Market - Brazil
- 10.7.7.1. Brazil: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
- 10.7.7.2. Brazil.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
- 10.7.7.3. Brazil: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
- 10.7.7.4. Brazil: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
- 10.7.7.5. Brazil: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
- 10.7.8. Intravenous immunoglobulin Market - Argentina
- 10.7.8.1. Argentina: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
- 10.7.8.2. Argentina.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
- 10.7.8.3. Argentina: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
- 10.7.8.4. Argentina: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
- 10.7.8.5. Argentina: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
11. Competitive Landscape
- 11.1. Expansion and Acquisition Analysis
- 11.1.1. Expansion
- 11.1.2. Acquisitions
- 11.2. Partnerships/Collaborations/Agreements/Exhibitions
12. Company Profiles
- 12.1. Baxter International Inc.
- 12.1.1. Company Overview
- 12.1.2. Financial Performance
- 12.1.3. Product Benchmarking
- 12.1.4. Recent Development
- 12.2. BDI Pharma Inc.
- 12.2.1. Company Overview
- 12.2.2. Financial Performance
- 12.2.3. Product Benchmarking
- 12.2.4. Recent Development
- 12.3. Biotest AG
- 12.3.1. Company Overview
- 12.3.2. Financial Performance
- 12.3.3. Product Benchmarking
- 12.3.4. Recent Development
- 12.4. China Biologics Products Inc.
- 12.4.1. Company Overview
- 12.4.2. Financial Performance
- 12.4.3. Product Benchmarking
- 12.4.4. Recent Development
- 12.5. CSL Behring
- 12.5.1. Company Overview
- 12.5.2. Financial Performance
- 12.5.3. Product Benchmarking
- 12.5.4. Recent Development
- 12.6. Grifols SA
- 12.6.1. Company Overview
- 12.6.2. Financial Performance
- 12.6.3. Product Benchmarking
- 12.6.4. Recent Development
- 12.7. Kedrion Biopharma
- 12.7.1. Company Overview
- 12.7.2. Financial Performance
- 12.7.3. Product Benchmarking
- 12.7.4. Recent Development
- 12.8. LFB Biotechnologies
- 12.8.1. Company Overview
- 12.8.2. Financial Performance
- 12.8.3. Product Benchmarking
- 12.8.4. Recent Development
- 12.9. Octapharma AG
- 12.9.1. Company Overview
- 12.9.2. Financial Performance
- 12.9.3. Product Benchmarking
- 12.9.4. Recent Development